Trava Health Review: What to Know Before You Subscribe

Trava Health is a direct-to-consumer telehealth platform that operates the same model as Henry Meds, Ivim Health, and Mochi Health: you fill out a questionnaire online, a licensed clinician reviews it, a partner compounding pharmacy fills the prescription, and a vial arrives at your door in an insulated box. The differentiator Trava puts forward is that one of the co-founders owns a sterile compounding pharmacy. That is unusual, and worth weighing carefully against the company's short track record.

The workflow looks like this:

1. 1.You complete a 10-minute online health intake covering medical history, current medications, weight, BMI, and goals.
2. 2.A clinician licensed in your state reviews the intake asynchronously, usually within 24 to 48 hours.
3. 3.If approved, the clinician writes a prescription for compounded semaglutide, tirzepatide, sermorelin, or NAD+.
4. 4.One of Trava's partner compounding pharmacies (Postmeds, EHT Pharmacy, Apostrophe, XeCare, Optimal Balance, or Promed) fills the order.
5. 5.The vial ships overnight on cold-chain ice packs to your address.
6. 6.Monthly refills auto-ship; dose changes happen through portal messaging with the clinician.

What Trava prescribes: - Compounded semaglutide blended with vitamin B12 for weight management - Compounded tirzepatide blended with vitamin B12 for weight management - Sermorelin for adults seeking growth hormone secretagogue therapy - NAD+ for adults pursuing longevity or energy support

What Trava does not do: - Dispense brand-name Wegovy, Zepbound, Ozempic, or Mounjaro. Those products come from Novo Nordisk and Eli Lilly through their pharmacy supply chains, not through compounding. - Accept insurance. Compounded weight-loss medications are not covered by any major US insurance plan. - Provide in-person care. Every interaction is virtual. - Replace your primary care physician.

The compounded semaglutide product is a copy of the active ingredient in Wegovy and Ozempic, prepared by a 503A or 503B pharmacy and combined with cyanocobalamin (vitamin B12). The compounded tirzepatide product is a copy of the active ingredient in Zepbound and Mounjaro, prepared the same way. The active molecules are identical to the brand drugs at the chemical level. The finished products are not FDA-approved as finished dosage forms.

Brand-name tirzepatide has rigorous trial data behind it. The SURMOUNT-1 trial showed mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg weekly doses over 72 weeks (Jastreboff et al., 2022). The SURMOUNT-2 trial in patients with type 2 diabetes confirmed clinically meaningful weight loss at the same doses (Garvey et al., 2023). Brand-name semaglutide showed roughly 14.9% mean weight reduction in the STEP-1 trial at 2.4 mg weekly over 68 weeks (Wilding et al., 2021). Compounded products from Trava and similar providers do not have their own trial data; they ride on the brand evidence by chemical equivalence.

For comparison reviews of competing telehealth providers, see Henry Meds reviews, Ivim Health reviews, Mochi Health reviews, Marek Health reviews, and the Vitastir tirzepatide review.

Trava's pricing is one of the lowest entry points in the compounded GLP-1 segment. The numbers below reflect what was published on taketrava.com in early 2026; verify current pricing on the live site because telehealth GLP-1 prices have shifted multiple times in the past 18 months.

Compounded semaglutide + B12: - Starting dose: ~$88.65 to $119.96 per month - Mid doses: typically $150 to $220 per month as you titrate up - The "starting at" price covers the lowest dose only; expect to pay more once you reach therapeutic levels

Compounded tirzepatide + B12: - 2.5-5 mg weekly: ~$197.98 per month - 7.5-10 mg weekly: ~$260 to $310 per month - 12.5 mg weekly: ~$340 per month - 15 mg weekly: ~$387.98 per month - Quarterly prepay: roughly $360/month at the 15 mg level (about 7% discount)

Sermorelin: starting at ~$157.91 per month for the lowest dose.

NAD+: starting at ~$116.31 per month for the lowest dose.

What is included in every plan: - Initial clinician consultation (asynchronous) - The medication vial - Insulin syringes and alcohol prep pads - Free overnight cold-chain shipping - Portal messaging access for dose adjustments - No membership or hidden fees per the company's marketing

Comparison to brand-name products: - Brand Wegovy list price: ~$1,349 per month, NovoCare self-pay around $499 per month - Brand Zepbound list price: ~$1,060 per month, LillyDirect self-pay around $349 to $549 per month depending on dose - Brand Mounjaro and Ozempic similarly priced when paid out of pocket

Comparison to competitor telehealth providers: - Henry Meds compounded tirzepatide: roughly $300 per month flat - Ivim Health compounded tirzepatide: roughly $270 to $370 per month - Mochi Health: roughly $260 to $375 per month - Vitastir: roughly $200 to $400 per month - Citizen Meds: comparable mid-tier pricing - Hims weight loss: roughly $199 to $349 per month for compounded semaglutide - Ro weight loss: typically higher because they often route to brand products

Trava's entry price for compounded semaglutide ($119.96) is genuinely among the lowest in the segment. The tirzepatide pricing sits in the mainstream mid-range. To model your annual cost across providers, run the peptide cost calculator and cross-reference with how much is semaglutide and tirzepatide cost with insurance.

Hidden cost factors to verify: - Dose escalation: does the next-higher dose tier increase your monthly bill automatically? On Trava, yes. - Cancellation: can you skip or cancel a month before it ships? Trava's policy is documented but verify it before subscribing. - Refunds for adverse events: if you stop the medication after one shipment due to side effects, Trava's "money back guarantee" appears in marketing copy but the specific terms are not always public. - Switching providers mid-titration: if you cancel after you have escalated, your next provider needs documentation of your current dose. Save your portal records.

The single most important question for any compounded GLP-1 provider is not the price. It is whether the people writing your prescription and the pharmacy filling it meet basic standards. Trava holds up reasonably well on most of these checks, but the framework matters because the answers can shift quickly.

1. State licensure of the prescribing clinician. Your prescription must come from a clinician licensed in your state, not just any state. Trava staffs clinicians across dozens of states; verify yours is covered during intake. If the company refuses to identify the specific clinician who wrote your prescription, that is a red flag. Cross-reference the clinician's name with your state medical board.

2. State licensure and accreditation of the compounding pharmacy. Trava lists six pharmacy partners: Postmeds (Truepill), EHT Pharmacy (Curexa), Apostrophe Pharmacy, XeCare, Optimal Balance Pharmacy, and Promed Pharmacy (Wells American). All are publicly identifiable, which is good practice. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation and FDA 503A or 503B registration on each pharmacy's site.

3. Quality testing of finished product. Trava states that batches are tested by Eagle Analytical, an FDA-registered laboratory. Independent batch testing is one of the strongest legitimacy signals in compounded products and most providers do not advertise it. Ask for a recent certificate of analysis if you want to verify before subscribing.

4. Disclosed formulation. Trava's products are tirzepatide or semaglutide blended with vitamin B12 (cyanocobalamin). Both additives are well-tolerated and the practice of including B12 is common across compounded GLP-1 providers. The exact concentration in mg/mL should be on every vial label. If the label is missing concentration data, do not use the product.

5. Clear refund and cancellation policy. Trava advertises a "money back guarantee" but the specific terms vary. Before prepaying, screenshot the cancellation policy and refund window. The general rule for any compounded product: never prepay more than one to three months until you have seen quality and responsiveness firsthand.

6. Provider responsiveness and dose escalation logic. Trava's standard support response window is 24 hours. The mid-2025 complaint pattern (orders delayed 2+ weeks, tickets unanswered for 8 days or more) suggests this standard slips during demand spikes. A legitimate provider will respond to dose change requests within 48 hours and will review your weight, side effect history, and any labs before approving an escalation.

7. Regulatory transparency. Compounded tirzepatide and semaglutide are legal under FDA section 503A only when the brand product is on the FDA shortage list, when a patient has a documented allergy to a brand component, or when the dose required is not commercially available. The shortage status has changed multiple times. As of late 2024, FDA removed both tirzepatide and semaglutide from the shortage list, then faced legal challenges, then partially reinstated some allowances. A legitimate provider will tell you exactly which legal basis they are operating under and how it applies to your prescription.

A pharmacovigilance review of FDA Adverse Event Reporting System data found compounded GLP-1 products had higher reporting odds ratios for abdominal pain, suicidality, and cholecystitis compared to FDA-approved products (Hoffman et al., 2025). The signal does not prove that compounded products are inherently more dangerous; it could reflect dosing errors, inconsistent concentrations, or reporting bias. The takeaway is that quality control variability matters, and a transparent pharmacy partner is a real benefit.

For the broader regulatory context, see FDA peptide crackdown 2026, are peptides legal, and is compound tirzepatide safe.

When your first Trava shipment arrives, the box should contain a few specific things. If anything is missing or unclear, contact Trava before injecting anything.

The vial. A multi-dose vial of compounded semaglutide or tirzepatide blended with B12. The label must show: - Drug name (semaglutide or tirzepatide) with B12 disclosure - Concentration in mg/mL - Total volume in mL - Lot or batch number - Expiration date - Compounding pharmacy name - Storage instructions (typically refrigerate between 2 to 8 degrees C)

Insulin syringes. Usually 30-unit or 50-unit U-100 insulin syringes with permanently attached needles, typically 6 mm or 8 mm in length. The syringe size should match the dose volume you need to draw. If you are unsure how to read your syringe, see how to draw tirzepatide and insulin syringe sizes for peptides.

Alcohol prep pads. A handful of single-use sterile alcohol pads for cleaning the vial stopper and your injection site.

A sharps container or instructions for safe needle disposal. Some providers include one; others ask you to source it locally. Never put used needles in regular trash.

A printed dosing instruction sheet. This should specify your weekly dose in milligrams, the exact volume to draw in units (since insulin syringes measure in units, not milligrams), and the rotation schedule for injection sites. If your sheet only lists milligrams without the unit conversion, calculate the volume yourself before drawing the first dose. Use the tirzepatide unit converter or semaglutide unit converter.

The B12 question. Trava's products include vitamin B12 (cyanocobalamin) at low supplemental doses. B12 does not affect the GLP-1 mechanism of action. It is included partly because B12 deficiency can worsen the fatigue some patients feel during weight loss, and partly because B12 is generally regarded as safe and easy to source. If you are already taking a B12 supplement separately, the additional B12 from the injection is unlikely to cause harm but is also unlikely to add benefit.

What clinical support looks like. After your first shipment, you can message your clinician through the portal for dose adjustments, side effect questions, and refill timing. Trava's stated standard is 24-hour response. The mid-2025 complaint wave suggests this slipped during peak demand. If you message and do not hear back within 48 hours, follow up; if you still do not hear back, that is meaningful data about whether to renew.

What clinical support does not look like. Trava is not your primary care physician. They will not order routine labs (CBC, comprehensive metabolic panel, lipid panel, HbA1c) unless you specifically request and pay for them. They will not coordinate care with your other providers. They will not see you in person if something serious happens. For lab-driven weight loss programs, Marek Health is a higher-touch but more expensive alternative. For the framework on what labs to run, see labs to check before peptides.

Trava has a small but meaningful review footprint. As of early 2026, the Trustpilot page for taketrava.com sits at roughly 59 reviews, which is the smallest review pool among major compounded GLP-1 telehealth providers. That alone is a context point: Henry Meds, Hims, and Mochi each have hundreds to thousands of reviews. A small sample makes both the positives and the negatives statistically less stable.

The dominant positive themes: - Pricing is described as competitive and transparent, with the entry-level semaglutide cost called out as one of the lowest available - Many reviewers describe the intake process as fast and the clinician approval as smooth - Free overnight shipping is praised, especially compared to providers who use 5 to 7 day ground shipping - Several reviewers report meaningful weight loss results within 12 to 16 weeks of starting tirzepatide, which aligns with the trial data (Jastreboff et al., 2022) - The pharmacy founder background is cited by some users as a reason they chose Trava over competitors

The dominant complaint themes: - Customer service responsiveness deteriorated during mid-2025 demand surges. Reviewers report tickets sitting open for a week or more without a substantive response. - Order delays of 2 weeks or longer for refills, with no proactive communication about the delay - Provider response quality variability. Some reviewers report thoughtful, individualized responses; others report what feel like template replies - Difficulty cancelling subscriptions or getting refunds for shipments that were already in transit - Confusion about dose escalation pricing (the next tier costs more, and not every customer realizes that until the charge appears)

The pharmacovigilance backdrop. Compounded GLP-1s as a category have a higher rate of FDA Adverse Event Reporting System events compared to brand products (Hoffman et al., 2025). Most events were gastrointestinal, consistent with the brand drug side effect profile. The most concerning signals were for severe abdominal pain, cholecystitis, and reports of suicidality. None of the published analyses point to Trava specifically, but the category-level signal is a reason to take side effect monitoring seriously regardless of provider.

How to read a small-sample review pool. A 59-review Trustpilot is light enough that a single coordinated push from happy or unhappy customers can shift the average score by half a star. Read individual reviews from the past 90 days, look for specific operational details (shipment numbers, response times, refund outcomes), and discount any review that reads like marketing or revenge. The pattern over time matters more than any single voice.

For comparison perspective on competitor review pools, see Hims weight loss reviews, Ro weight loss reviews, Found weight loss reviews, Sequence weight loss reviews, Sesame Care weight loss reviews, and Calibrate weight loss reviews.

The honest answer to "is Trava right for me" depends on which trade-offs you can absorb. The trade-offs in compounded GLP-1 telehealth are real, and they apply to every provider in the category, not just Trava.

Trava is a reasonable fit if: - You are paying out of pocket because your insurance does not cover Wegovy or Zepbound, and the brand price is unsustainable - You are comfortable with asynchronous care and do not need frequent live conversations with a clinician - You can tolerate the regulatory uncertainty around compounded GLP-1s - You have a primary care physician separately for routine monitoring (lipids, A1c, kidney function, lipase, mental health screening) - You are early in your weight loss journey at lower doses where the price advantage is largest - You value overnight shipping and competitive entry pricing over high-touch coaching

Trava is probably not the right fit if: - Your insurance covers brand Wegovy or Zepbound at any reasonable copay - You want monthly live video visits with a clinician (try Sequence or Form Health) - You want labs included in the program (try Marek Health or your primary care) - You have a complicated medical history (history of pancreatitis, medullary thyroid carcinoma, MEN2, gastroparesis, eating disorder, severe gallbladder disease) that requires close in-person monitoring - You want the highest-volume review history before subscribing (try Henry Meds or Hims) - You are pregnant, planning pregnancy within 2 months of stopping, or breastfeeding (no GLP-1 is appropriate in this scenario regardless of provider) - You need same-day or live human support for any concern

A note on the holistic vs medication-only debate. GLP-1 medications work best inside a broader framework that addresses food environment, sleep, movement, and stress. Trava is a medication delivery service, not a holistic program. If you need behavior change support, you will need to source it elsewhere through a registered dietitian, therapist, or coaching service. For the framework, see tirzepatide diet plan and semaglutide vs tirzepatide for weight loss.

A note on stopping. Most patients regain weight after stopping GLP-1 medications, with one large analysis showing roughly two-thirds of weight lost is regained within 12 months of discontinuation. Plan for either long-term use (1+ years), a structured taper into maintenance dosing, or robust behavior change before you start. See maintenance dose tirzepatide and stopping tirzepatide.

The most important comparison is not Trava versus another compounder. It is Trava versus the brand product, because the brand product is what every compounded version is trying to copy.

The active molecule is the same. Compounded tirzepatide from a quality 503A pharmacy contains the same tirzepatide molecule as Eli Lilly's Zepbound. Compounded semaglutide contains the same semaglutide molecule as Novo Nordisk's Wegovy and Ozempic. The pharmacology is the same. The receptor binding is the same. The expected efficacy at equivalent milligram doses is the same on paper.

Three things differ in practice:

1. 1.Concentration consistency. Brand products are manufactured to FDA-approved specifications with batch-to-batch consistency tested in commercial-scale operations. Compounded products vary by pharmacy. Eagle Analytical batch testing (which Trava advertises) is one mitigation. Without independent testing, concentration can drift, which means the milligrams-per-unit conversion you use to draw your dose may not match the label.

1. 1.Excipient and additive differences. Brand Zepbound contains tirzepatide plus specific excipients (sodium phosphate, glycerol, sodium chloride, water for injection) at a known pH. Trava's compounded tirzepatide adds vitamin B12 and may use different excipients depending on the pharmacy. The pharmacokinetic profile of brand tirzepatide is well-characterized: half-life around 5 days, peak plasma concentration 8 to 72 hours after subcutaneous injection (Bastin et al., 2022). Compounded products are presumed to behave similarly but compounded-specific PK studies do not exist.

1. 1.Regulatory and quality oversight. FDA inspects brand manufacturing facilities regularly. State boards of pharmacy and FDA inspect compounding pharmacies on different cycles, with different rigor. The FAERS pharmacovigilance signal for compounded GLP-1s (Hoffman et al., 2025) reflects this gap.

The price difference is real. A patient on tirzepatide at the 10 mg weekly dose pays roughly $310 per month with Trava versus roughly $499 per month with LillyDirect Zepbound self-pay. Over a year that is $2,268 versus $5,988, a $3,720 difference. For many patients, that gap is the entire reason compounded products exist.

The decision tree: - If insurance covers brand Wegovy or Zepbound at any copay you can sustain, take the brand product. The clinical and regulatory clarity is worth the difference. - If insurance does not cover brand and you can afford LillyDirect or NovoCare self-pay, those are the next-best option. You get FDA-approved product with manufacturer support. - If self-pay brand is not affordable, compounded providers like Trava, Henry Meds, Ivim, Mochi, or Vitastir become reasonable choices, ranked by which one passes the legitimacy checklist for you. - If you are still uncertain, talk to your primary care physician. Compounded GLP-1s exist in a gray zone that is partly legal, partly clinical, and entirely personal.

For deeper comparisons, see where to buy tirzepatide, Wegovy vs Zepbound, Mounjaro vs Zepbound, and tirzepatide cost with insurance.

Most of the regret around compounded GLP-1 services comes from a small set of preventable mistakes. None of these are unique to Trava, but they show up regularly in the review patterns.

Prepaying multiple months on the first subscription. The quarterly discount looks attractive, but you do not yet know whether the pharmacy will deliver on time, whether the medication will agree with you, or whether your insurance situation might change. Pay for one month, evaluate quality and responsiveness, then consider longer commitments.

Skipping the legitimacy check on the assigned pharmacy partner. Trava lists six pharmacy partners. Your specific orders will come from one (or more) of them. Look up the pharmacy's PCAB accreditation and state licensure on the relevant state board of pharmacy site. The assigned pharmacy can vary by state and by month.

Ignoring the unit conversion. Your dose is prescribed in milligrams. Your insulin syringe measures in units. At 10 mg/mL concentration, 2.5 mg equals 25 units. At a different concentration the math changes. If the dosing instructions only list milligrams, do the math yourself before drawing. See how to draw tirzepatide.

Storing the vial wrong. Compounded semaglutide and tirzepatide need refrigeration between 2 and 8 degrees C from the moment they arrive. Letting the vial sit at room temperature for hours degrades the peptide. If your shipment arrives warm or with melted ice packs, contact the provider and document the temperature before injecting. See how to store peptides and does tirzepatide need refrigeration.

Escalating doses too fast. The brand titration ladder for tirzepatide is 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg if needed, then up to 15 mg. The slower titration reduces gastrointestinal side effects. Some compounded providers offer aggressive escalation; resist the temptation. The trial data is built on the standard ladder (Jastreboff et al., 2022).

Not reporting side effects to the clinician. Persistent vomiting, severe abdominal pain, signs of pancreatitis (intense epigastric pain radiating to the back), gallbladder pain, or unusual symptoms should be reported through the portal. The clinician needs the data to manage your dose, and the FAERS pharmacovigilance system needs the reports to monitor compounded product safety overall (Hoffman et al., 2025). See tirzepatide long-term side effects, can tirzepatide cause anxiety, and tirzepatide and gallbladder.

Stacking compounded tirzepatide with other peptides without telling anyone. If you are also using BPC-157, retatrutide, AOD-9604, or any other peptide, the clinician needs to know. Some combinations have not been studied. Use the peptide interaction checker before adding anything.

Assuming the medication does the work alone. GLP-1s reduce hunger and slow gastric emptying. They do not change food preferences, repair sleep, or build muscle. The patients who keep weight off long-term combine medication with structured eating, resistance training, and protein adequacy. See tirzepatide and muscle loss and protein on GLP-1.